NEUROCRINE BIOSCIENCES INC Equity Securities, FV-NI, Restricted
NEUROCRINE BIOSCIENCES INC (NBIX) had Equity Securities, FV-NI, Restricted of $102.10 million as of 2022-12-31, per its 10-K filed 2023-02-09.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecuritiesFvNiRestricted · last filed 2023-02-09
- 2022-12-31: Equity Securities, FV-NI, Restricted $102.10M.
- 2021-12-31: Equity Securities, FV-NI, Restricted $63.70M.
- 2021-09-30: Equity Securities, FV-NI, Restricted $35.30M.
- 2021-06-30: Equity Securities, FV-NI, Restricted $38.90M.
| Period end | Equity Securities, FV-NI, Restricted | Equity Securities, FV-NI, Restricted as first filed |
|---|---|---|
| 2022-12-31 | $102.10M 10-K · filed 2023-02-09 | |
| 2021-12-31 | $63.70M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $35.30M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $38.90M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $38.90M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $38.20M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $43.70M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $50.70M 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $39.40M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $55.90M 10-K · filed 2021-02-05 | $55.87M 10-K · filed 2020-02-07 |
| 2019-09-30 | $48.91M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $77.36M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $56.40M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $0.00 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |